XBiotech Announces Public Offering of Common Shares
AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions. XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares.
Piper Jaffray is acting as the sole underwriter in the offering.
Net proceeds of the offering will be used primarily to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis and for general corporate and working capital purposes. Completion of the offering is subject to customary closing conditions.
The common shares are being offered pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the XBiotech common shares. The prospectus supplement will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov, or may be obtained, when available, by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at email@example.com, or by phone at (800) 747-3924. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca13.7.2020 19:31:34 CEST | Press release
Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research collaboration with AstraZeneca. The collaboration was initiated in September 2015 to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the delivery of AstraZeneca's nucleic acid therapeutic compounds. The evaluation of the potential for a further collaboration now runs to the end of 2020. Contact information: Per Walday, CEO firstname.lastname@example.org Mobile: +47 917 93 429 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-
EVS Broadcast Equipment reports update of share buyback program13.7.2020 17:45:00 CEST | Press release
Publication on July 13, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between July 6, 2020 and July 10, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)06/07/20202,11216.427616.5016.36 34,695 07/07/20202,10016.507816.6216.38 34,666 08/07/20202,50016.409116.4416.30 41,023 09/07/20201,89816.363216.4216.30 31,057 10/07/20202,20216.285916.3816.24 35,862 Total10,812 16.3987 16.62 16.24 177,303 As of July 10, 2020, and since the start of the buyback program, EVS has bought 95,521 shares at an average price of EUR 15,6592, representing in total EUR 1,495,785. After aforementioned transactions the total number of ow
XBT Provider AB (Publ) Publishes Half Year Interim Report 202013.7.2020 17:30:00 CEST | Press release
XBT Provider AB (Publ) Publishes Half Year Interim Report Stockholm, July 13, 2020 -- XBT Provider AB (Publ) ("XBT" or the "Company") is pleased to announce that the Interim Report for the period ended 30 June 2020 has been posted on the Company's website. The Guarantor, CoinShares (Jersey) Limited, has also provided an unaudited set, of their financial statements for the period ending on 30 June 2020, which are also posted on the Company's website. Interested persons may access an electronic copy of these documents at https://coinshares.com/etps/xbt-provider/investor-resources About XBT Provider XBT Provider AB (Publ) (XBT Provider), a CoinShares company, is the Swedish-domiciled issuer of the Bitcoin Tracker One (SE0007126024), Bitcoin Tracker Euro (SE0007525332), Ether Tracker One (SE0010296574) and Ether Tracker Euro (SE0010296582), Litecoin Tracker One (SE0011414465), Litecoin Tracker Euro (SE0011414457), XRP Tracker One (SE0011414481), XRP Tracker Euro (SE0011414473), series of c
Valmet’s comment on Alfa Laval’s tender offer for Neles’ shareholders13.7.2020 16:00:00 CEST | Press release
Valmet Oyj’s press release July 13, 2020 at 5:00 p.m. EET Valmet has today become aware of Alfa Laval’s announcement on public cash tender offer for all shares in Neles. Valmet completed 14.88 percent share acquisition of Neles’ shares from Solidium Oy on July 1, 2020. “Neles is a good quality company with a strong position in the pulp and paper industry and other process industries. Valmet and Neles have a common heritage, serve similar global industries and benefit from same global megatrends. Valmet sees a good amount of value in Neles and with the previously announced share acquisition our target is to participate in developing the company further. Therefore, as a Neles shareholder, Valmet does not consider Alfa Laval’s tender offer to be beneficial for Neles. Valmet will continue as an active shareholder of Neles,” says Pasi Laine, President and CEO of Valmet. Valmet acquires 14.9% ownership in the future Neles Valmet completes 14.9% ownership acquisition of Neles VALMET Corporate
Verisk to Announce Fiscal Second-Quarter 2020 Results on August 4, 202013.7.2020 15:29:14 CEST | Press release
Jersey City, NJ, July 13, 2020 (GLOBE NEWSWIRE) -- Verisk (Nasdaq:VRSK), a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services, will report its financial results for the fiscal second quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the market close. The press release, with accompanying financial information, will be posted on the Verisk investor website at http://investor.verisk.com. Verisk’s management team will host a live audio webcast to discuss the financial results and business highlights on Wednesday, August 5, 2020, at 8:30 a.m. EDT (5:30 a.m. PDT, 1:30 p.m. BST). All interested parties are invited to listen to the live event via webcast on the Verisk investor website at http://investor.verisk.com. The discussion will also be available through dial-in number 1-877-755-3792 for U.S./Canada participants or 512-961-6560 for international participants. A replay of the webcast will be available for 30
CNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management Platform13.7.2020 13:02:10 CEST | Press release
Boston, July 13, 2020 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that CNA has transitioned to AIR’s Touchstone solution as its primary catastrophe risk modeling platform. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “We are excited to leverage AIR’s powerful catastrophe modeling solution to support our multiple lines of business during the underwriting process,” said Tom Stone, vice president of aggregation and catastrophe management at CNA. “AIR has a track record of providing scientifically credible models and combined with Touchstone, this complete solution will provide us with more analytics to make risk management, pricing, and risk selection decisions.” As part of the agreement, CNA is accessing Touchstone in the AIR Cloud as a secure and cost-efficient alternative to on-premise deployment. CNA is also licensing AIR’s Web Services to connect to AIR’s cloud infrastructure and obtain hazard, and loss analysis output in seconds; and Touchstone APIs to